Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Burcu Çakar"'
Autor:
Bülent Karabulut, Burcu Çakar
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 630-639 (2024)
Introduction: Although long-term survival in patients with metastatic colorectal cancer (mCRC) is limited, treatments for third-line and later treatment are now recommended. We describe a patient who achieved long-term survival when they received thi
Externí odkaz:
https://doaj.org/article/cab300c40ec24dde8134b77559ec4501
Autor:
Vahit Özmen, Burcu Çakar, Erhan Gökmen, Mustafa Özdoğan, Nilufer Güler, Cihan Uras, Engin Ok, Orhan Demircan, Abdurrahman Işıkdoğan, Pınar Saip
Publikováno v:
European Journal of Breast Health, Vol 15, Iss 3, Pp 183-190 (2019)
Objective: Breast cancer is a heterogenous disease, and genetic profiling helps to individualize adjuvant treatment. The Oncotype DX is a validated test to predict benefit of adjuvant systemic treatment. The aims of this study are to determine the co
Externí odkaz:
https://doaj.org/article/bad25b22085c4054ab521cf0b82bb85f
Publikováno v:
European Journal of Breast Health, Vol 14, Iss 4, Pp 211-217 (2018)
Objective: Inflammatory breast cancer (IBC) has an unfavourable prognosis despite the advances made in the treatment of breast cancer. Our study aimed to define immunohistochemistry-based surrogate subtype distribution to determine whether the breast
Externí odkaz:
https://doaj.org/article/7ceecf9ea4584fd8a281e9300618c3f2
Autor:
Umut Varol, Burcu Çakar, İbrahim Yıldız, Ceyda Tunakan Dalgıç, Hatice Özışık, Melih Özışık, Burçak Karaca, Bülent Karabulut, Rüçhan Uslu
Publikováno v:
European Journal of Breast Health, Vol 10, Iss 1, Pp 42-46 (2014)
Objective:Triple negative and human epidermal growth factor receptor 2 (Her2) positive breast tumors are characterized by the absence of expression of estrogen and progesterone receptors and with either Her2 expression or not. Generally, they are lar
Externí odkaz:
https://doaj.org/article/0c251cc66c13441aa52371fc8a61d40d
Autor:
Kadir Eser, Pinar Saip, Erdem Cubukcu, Fuat Demirelli, Ozkan Alan, Zuleyha Calikusu, Aykut Bahceci, Ali Alkan, Hacer Demir, Mahmut Büyükşimşek, Cemile Karadeniz, Erhan Gokmen, Naziye Ak, Mehmet Bilici, Altay Aliyev, Turkkan Evrensel, Oznur Bal, Atakan Demir, Özge Keskin, Nilgün Yildirim, Saadettin Kilickap, Semra Paydas, Atike Gökçen Demiray, Kezban Nur Pilanci, Ali Gökyer, Perran Fulden Yumuk, Birol Yildiz, Duygu Ilke Cikman, Ismail Beypinar, Taner Korkmaz, Sinan Yavuz, Burcu Çakar, Erkan Arpaci, Gulsah Seydaoglu, Ferhat Ferhatoglu, Ahmet Z. Sahin, Gulcan Bulut, Serkan Degirmencioglu, Cengiz Karacin, Mutlu Dogan, Havva Yesil Cinkir, Kerem Okutur, Semiha Urvay, Deniz Işik, Melih Simsek, Osman Kostek, Meltem Baykara, Salim Basol Tekin, Deniz Yamac
Publikováno v:
Cancer Investigation. 39:473-481
Aim: The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method: Retrospective analysis of T-DM1 results of human epidermal grow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e995dc25bd5d60e4fc0b04e58d82c9ea
https://doi.org/10.1080/07357907.2021.1933011
https://doi.org/10.1080/07357907.2021.1933011
Publikováno v:
Turkish thoracic journal. 23(4)
Epidermal growth factor receptor mutations are the second most common oncogenic driver event in non-small cell lung cancer. We aimed to compare the first generation erlotinib treatment with the second generation afatinib treatment in patients with no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::03a523c309e87cf8c9d3f40f383e4a81
https://pubmed.ncbi.nlm.nih.gov/35848437
https://pubmed.ncbi.nlm.nih.gov/35848437
Autor:
Yeşim ERALP, İzzet DOĞAN, Sercan Aksoy, Burcu ÇAKAR, Gül BAŞARAN, Özlem ERCELEP, Nil MOLİNAS MANDEL, Taner KORKMAZ, Erhan GÖKMEN, Adnan AYDINER, Pınar SAİP
Publikováno v:
Cancer Research. 83:P3-02
Background: Although HER2 is an aggressive subtype of BC, the outcomes have improved over the past two decades due to advances in targeted therapies. Here, we present data of HER2-positive subset from the multicenter registry study of the Turkish Onc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f42d288597a877ba9328aed287ae43a1
https://doi.org/10.1158/1538-7445.sabcs22-p3-02-06
https://doi.org/10.1158/1538-7445.sabcs22-p3-02-06
Autor:
Nevin Oruc, Muhtar Sinan Ersin, Burcu Çakar, Ayşe Caner, Taylan Özgür Sezer, Serhat Bor, Fatih Tekin, Rukiye Vardar, Şaziye Burçak Karaca, Sevgi Erdem, Nevra Elmas, Ayfer Haydaroğlu, Nalan Gülşen Ünal, Başak Doğanavşargil, Ahmet Aydin, Halit Batuhan Demir, Ilker Turan, Serdar Özkök, Özgür Firat, Ahmet Ömer Özütemiz, Bulent Karabulut, Deniz Yalman, Murat Sezak
Publikováno v:
Ege Tıp Dergisi. :6-16
Amaç: Bu çalışmada mide kanserinin (MK) epidemiyolojik ve genel sağkalım (GSK) özelliklerinin araştırılması amaçlanmıştır. Gereç Yöntem: Ege Üniversitesi Kanserle Savaş Uygulama ve Araştırma Merkezine (EÜKAM) 1992- 2017 yıllar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35633deaa928f5f6fd6f4d550fbe376e
https://doi.org/10.19161/etd.815041
https://doi.org/10.19161/etd.815041
Autor:
Serdar Özkök, Ilker Turan, Gülin Kavakalan, Nevin Oruç, Ahmet Aydin, Rukiye Vardar, Burcu Çakar, Ahmet Ömer Özütemiz, Nalan Gülşen Ünal, Sinan Ersin, Serhat Bor, Bulent Karabulut, Ayfer Haydaroğlu, Murat Sezak, Halit Batuhan Demir, Karaca B, Fatih Tekin, Ayşe Caner
Publikováno v:
Ege Tıp Dergisi
Amaç: Bu çalışmada özofagus kanserlerinin (ÖK) epidemiyolojik ve genel sağkalım (GSK) özelliklerininaraştırılması amaçlanmıştır.Gereç Yöntem: Ege Üniversitesi Kanserle Savaş Uygulama ve Araştırma Merkezinin 1992-2017 yıllarıa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27b71bfa24eb744294ec107df6bb408d
https://doi.org/10.19161/etd.815112
https://doi.org/10.19161/etd.815112
Autor:
Erhan Gokmen, Ozkan Alan, Gul Basaran, Serdar Turhal, Ozgur Tanriverdi, Yesim Eralp, Burcak Karaca, Semra Paydas, Fatma Paksoy Turkoz, Burcu Çakar, Sevgi Topcu, Gulhan Ipek Deniz, Bulent Karabulut, Seyda Gunduz, Osman Kostek, Taner Korkmaz, Umut Demirci, Sema Sezgin Goksu
Publikováno v:
Cancer Research. 80:P5-11
Background: Ribociclib combined with endocrine therapy (ET) have demonstrated efficacy in patients with hormone receptor (HR) positive advanced breast cancer (ABC) who experienced progression during prior ET. However, there are scarce data chemo-endo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a18cbf7d094af11a0281bc8c35ee0c0
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-19
https://doi.org/10.1158/1538-7445.sabcs19-p5-11-19